188 related articles for article (PubMed ID: 29879184)
1. Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers.
Qiu L; Levine K; Gajiwala KS; Cronin CN; Nagata A; Johnson E; Kraus M; Tatlock J; Kania R; Foley T; Sun S
PLoS One; 2018; 13(6):e0198374. PubMed ID: 29879184
[TBL] [Abstract][Full Text] [Related]
2. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
3. Co-crystal structures of PTK6: With Dasatinib at 2.24 Å, with novel imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 Å resolution.
Thakur MK; Birudukota S; Swaminathan S; Battula SK; Vadivelu S; Tyagi R; Gosu R
Biochem Biophys Res Commun; 2017 Jan; 482(4):1289-1295. PubMed ID: 27993680
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of the kinase domain of human protein tyrosine kinase 6 (PTK6) at 2.33 Å resolution.
Thakur MK; Kumar A; Birudukota S; Swaminathan S; Tyagi R; Gosu R
Biochem Biophys Res Commun; 2016 Sep; 478(2):637-42. PubMed ID: 27480927
[TBL] [Abstract][Full Text] [Related]
5. Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition.
Tsui T; Miller WT
Biochemistry; 2015 May; 54(20):3173-82. PubMed ID: 25940761
[TBL] [Abstract][Full Text] [Related]
6. PTK6 Localized at the Plasma Membrane Promotes Cell Proliferation and MigratiOn Through Phosphorylation of Eps8.
Shin WS; Shim HJ; Lee YH; Pyo M; Park JS; Ahn SY; Lee ST
J Cell Biochem; 2017 Sep; 118(9):2887-2895. PubMed ID: 28214294
[TBL] [Abstract][Full Text] [Related]
7. Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer.
Ludyga N; Anastasov N; Gonzalez-Vasconcellos I; Ram M; Höfler H; Aubele M
Mol Biosyst; 2011 May; 7(5):1603-12. PubMed ID: 21380407
[TBL] [Abstract][Full Text] [Related]
8. Targeting protein tyrosine kinase 6 in cancer.
Gilic MB; Tyner AL
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188432. PubMed ID: 32956764
[TBL] [Abstract][Full Text] [Related]
9. Hsp90 rescues PTK6 from proteasomal degradation in breast cancer cells.
Kang SA; Cho HS; Yoon JB; Chung IK; Lee ST
Biochem J; 2012 Oct; 447(2):313-20. PubMed ID: 22849407
[TBL] [Abstract][Full Text] [Related]
10. Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.
Falkenberg N; Anastasov N; Höfig I; Bashkueva K; Lindner K; Höfler H; Rosemann M; Aubele M
Mol Oncol; 2015 Jan; 9(1):282-94. PubMed ID: 25241146
[TBL] [Abstract][Full Text] [Related]
11. PTEN is a protein phosphatase that targets active PTK6 and inhibits PTK6 oncogenic signaling in prostate cancer.
Wozniak DJ; Kajdacsy-Balla A; Macias V; Ball-Kell S; Zenner ML; Bie W; Tyner AL
Nat Commun; 2017 Nov; 8(1):1508. PubMed ID: 29142193
[TBL] [Abstract][Full Text] [Related]
12. Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor.
Zheng Y; Peng M; Wang Z; Asara JM; Tyner AL
Mol Cell Biol; 2010 Sep; 30(17):4280-92. PubMed ID: 20606012
[TBL] [Abstract][Full Text] [Related]
13. The alternative splice variant of protein tyrosine kinase 6 negatively regulates growth and enhances PTK6-mediated inhibition of β-catenin.
Brauer PM; Zheng Y; Evans MD; Dominguez-Brauer C; Peehl DM; Tyner AL
PLoS One; 2011 Mar; 6(3):e14789. PubMed ID: 21479203
[TBL] [Abstract][Full Text] [Related]
14. Vemurafenib Inhibits Active PTK6 in
Wozniak DJ; Hitchinson B; Gilic MB; Bie W; Gaponenko V; Tyner AL
Mol Cancer Ther; 2019 May; 18(5):937-946. PubMed ID: 30926642
[TBL] [Abstract][Full Text] [Related]
15. Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer.
Mathur PS; Gierut JJ; Guzman G; Xie H; Xicola RM; Llor X; Chastkofsky MI; Perekatt AO; Tyner AL
Mol Cancer Res; 2016 Jun; 14(6):563-73. PubMed ID: 26983689
[TBL] [Abstract][Full Text] [Related]
16. Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cells.
Ludyga N; Anastasov N; Rosemann M; Seiler J; Lohmann N; Braselmann H; Mengele K; Schmitt M; Höfler H; Aubele M
Mol Cancer Res; 2013 Apr; 11(4):381-92. PubMed ID: 23364537
[TBL] [Abstract][Full Text] [Related]
17. HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain.
Ai M; Qiu S; Lu Y; Fan Z
Cell Signal; 2013 Sep; 25(9):1754-61. PubMed ID: 23707532
[TBL] [Abstract][Full Text] [Related]
18. PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors.
Peng M; Emmadi R; Wang Z; Wiley EL; Gann PH; Khan SA; Banerji N; McDonald W; Asztalos S; Pham TN; Tonetti DA; Tyner AL
Oncotarget; 2014 Aug; 5(15):6038-48. PubMed ID: 25153721
[TBL] [Abstract][Full Text] [Related]
19. PTK6 promotes degradation of c-Cbl through PTK6-mediated phosphorylation.
Kang SA; Lee ST
Biochem Biophys Res Commun; 2013 Feb; 431(4):734-9. PubMed ID: 23352614
[TBL] [Abstract][Full Text] [Related]
20. Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK.
Brauer PM; Tyner AL
Biochim Biophys Acta; 2010 Aug; 1806(1):66-73. PubMed ID: 20193745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
